文献速递银屑病与炎症性皮肤病

布罗达鲁单抗对乌司奴单抗应答不佳银屑病患者的疗效与安全性:两项随机III期试验的亚组分析

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
PubMed 文献 · Br J Dermatol · 2018-12-27

该亚组分析基于两项随机III期试验,评估布罗达鲁单抗对乌司奴单抗应答不佳银屑病患者的疗效与安全性。第52周时,布罗达鲁单抗挽救治疗组PASI≥75%、≥90%和100%应答率分别为72.6%、58.1%和36.3%,高于继续乌司奴单抗组的61.7%、25.5%和5.4%。两组治疗中出现的不良事件暴露调整率相似。

要点

  • 对乌司奴单抗应答不佳者,布罗达鲁单抗挽救治疗第52周PASI≥75%应答率72.6%。
  • 继续乌司奴单抗组第52周PASI≥75%应答率为61.7%。
  • 布罗达鲁单抗组不良事件暴露调整率377.3/100患者年,乌司奴单抗组389.9/100患者年。

核心结论

  • 对乌司奴单抗应答不佳的患者,布罗达鲁单抗挽救治疗较继续乌司奴单抗改善皮肤清除结局。

研究设计与样本

  • III期AMAGINE-2/-3双盲随机对照试验的亚组分析。
  • 参与者年龄18-75岁,银屑病面积和严重程度指数(PASI)≥12,静态医生总体评估评分≥3,体表面积受累≥10%。
  • AMAGINE-2注册号NCT01708603,AMAGINE-3注册号NCT01708629。

主要发现

  • 在乌司奴单抗应答不佳患者中,布罗达鲁单抗挽救组第52周PASI≥75%、≥90%和100%改善应答率分别为72.6%、58.1%和36.3%。
  • 继续乌司奴单抗组第52周PASI≥75%、≥90%和100%改善应答率分别为61.7%、25.5%和5.4%。
  • 布罗达鲁单抗挽救组治疗中出现的不良事件暴露调整率为每100患者年377.3例,继续乌司奴单抗组为每100患者年389.9例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, has demonstrated superior efficacy and safety over ustekinumab as induction therapy for moderate-to-severe psoriasis. OBJECTIVES: To evaluate the efficacy and safety of brodalumab through week 52 in patients who had inadequate responses to ustekinumab. METHODS: A subgroup analysis of the phase III AMAGINE-2/-3 double-blind randomized controlled trials was performed. Participants were aged 18-75 years and had a Psoriasis Area and Severity Index (PASI) ≥ 12, static Physician's Global Assessment score ≥ 3 and involvement of ≥ 10% body surface area. The studies were registered at ClinicalTrials.gov: AMAGINE-2, NCT01708603; AMAGINE-3, NCT01708629. RESULTS: At baseline, patients with or without prior biologic experience who had an adequate response at week 16 on ustekinumab or brodalumab had lower rates of involved body surface area, PASI, prior biologic use, psoriatic arthritis and body mass index than patients who experienced inadequate response at or after week 16. Among patients who experienced inadequate response to ustekinumab, those rescued with brodalumab had PASI ≥ 75%, ≥ 90% and 100% improvement response rates of 72·6%, 58·1% and 36·3%, respectively, at week 52 compared with 61·7%, 25·5% and 5·4%, respectively, in patients who continued ustekinumab. Exposure-adjusted rates of treatment-emergent adverse events were similar among patients rescued with brodalumab (377·3 adverse events per 100 patient-years) and those who remained on ustekinumab (389·9 adverse events per 100 patient-years). CONCLUSIONS: Among patients who experienced inadequate responses to ustekinumab, rescue with brodalumab improved skin clearance outcomes compared with continuing ustekinumab.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Langley RG, Armstrong AW, Lebwohl MG, et al. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. Br J Dermatol. 2018. PMID: 30328108. doi:10.1111/bjd.17318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。